Imugene (ASX:IMU) received a notice of allowance from the Chinese patent office for City of Hope's patent application for the CD19-expressing oncolytic virus, onCARlytics, according to a Wednesday Australian bourse filing.
The patent protects the method of composition and method of use of onCARlytics through to 2038.
OnCARlytics is exclusively licensed to Imugene and is a CD19-expressing oncolytic virus that enters solid tumor cells, forcing them to express the CD19 protein on the cell surface, presenting a target for CD19-targeting therapies.
Its OASIS dose escalation trial of onCARlytics is being conducted at up to ten sites in the US, with up to around 40 patients proposed to take part.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.